The influence of donor age on the survival of solid and suspension intraparenchymal human embryonic nigral grafts
Identifieur interne : 000D92 ( Main/Corpus ); précédent : 000D91; suivant : 000D93The influence of donor age on the survival of solid and suspension intraparenchymal human embryonic nigral grafts
Auteurs : Thomas B. Freeman ; Paul R. Sanberg ; G. Michael Nauert ; Barbara D. Boss ; Dennis Spector ; C. Warren Olanow ; Jeffrey H. KordowerSource :
- Cell Transplantation [ 0963-6897 ] ; 1994.
Abstract
In many species, graft survival and graft-derived behavioral recovery are affected by the embryonic donor age. We compared the ability of solid and suspension grafts of human embryonic mesencephalic dopaminergic (DA) neurons at different embryonic stages to survive intraparenchymal transplantation into 6-OHDA lesioned immunosuppressed rats. Suspension grafts survived best when donor age was between postconception (PC) days 34 and 56. Transplants displayed numerous healthy tyrosine hydroxylase immunoreactive (TH-IR) neurons which sent extensive neuritic processes into the host striatum. Suspension grafts survived poorly when donor age was greater than 65 days. Solid implants displayed comparable viability of TH-IR neurons when donor age was between 44 and 65 days. No solid grafts contained TH-IR cells when donor tissue was older than 72 days. The suspension and solid methods of transplantation resulted in comparable survival of robust grafts, but solid grafts resulted in more intergraft variability than suspension grafts, particularly among the more marginal implants. Our results demonstrate that the upper limit for survival of human embryonic DA suspension grafts correlates well with the period of development of the human nigrostriatal pathway. The “window” for donor age of solid human embryonic DA grafts appears to be extended by about 9 days in comparison to suspension grafts. These data suggest that the upper age limit for grafting human mesencephalic DA neurons should be PC day 56 for suspension grafts, and PC day 65 for solid implants. Older donors are likely to produce grafts with fewer surviving DA neurons.
Url:
DOI: 10.1016/0963-6897(94)00048-O
Links to Exploration step
ISTEX:1AA361AFAC1D975EF627F0E0745195D0BC1BD003Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>The influence of donor age on the survival of solid and suspension intraparenchymal human embryonic nigral grafts</title><author><name sortKey="Freeman, Thomas B" sort="Freeman, Thomas B" uniqKey="Freeman T" first="Thomas B." last="Freeman">Thomas B. Freeman</name><affiliation><mods:affiliation>Division of Neurosurgery, University of South Florida, Columbia Drive, Suite 730, Tampa, FL 33606, USA</mods:affiliation></affiliation></author><author><name sortKey="Sanberg, Paul R" sort="Sanberg, Paul R" uniqKey="Sanberg P" first="Paul R." last="Sanberg">Paul R. Sanberg</name><affiliation><mods:affiliation>Division of Neurosurgery, University of South Florida, Columbia Drive, Suite 730, Tampa, FL 33606, USA</mods:affiliation></affiliation></author><author><name sortKey="Nauert, G Michael" sort="Nauert, G Michael" uniqKey="Nauert G" first="G. Michael" last="Nauert">G. Michael Nauert</name><affiliation><mods:affiliation>Woman's Center, Tampa, FL, USA</mods:affiliation></affiliation></author><author><name sortKey="Boss, Barbara D" sort="Boss, Barbara D" uniqKey="Boss B" first="Barbara D." last="Boss">Barbara D. Boss</name><affiliation><mods:affiliation>Hana Biologics, Inc., Alameda, CA, USA</mods:affiliation></affiliation></author><author><name sortKey="Spector, Dennis" sort="Spector, Dennis" uniqKey="Spector D" first="Dennis" last="Spector">Dennis Spector</name><affiliation><mods:affiliation>Hana Biologics, Inc., Alameda, CA, USA</mods:affiliation></affiliation></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation><mods:affiliation>Department of Neurology, Mount Sinai Medical Center, New York, NY, USA</mods:affiliation></affiliation></author><author><name sortKey="Kordower, Jeffrey H" sort="Kordower, Jeffrey H" uniqKey="Kordower J" first="Jeffrey H." last="Kordower">Jeffrey H. Kordower</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush Presbyterian Medical Center, Chicago, IL, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1AA361AFAC1D975EF627F0E0745195D0BC1BD003</idno><date when="1995" year="1995">1995</date><idno type="doi">10.1016/0963-6897(94)00048-O</idno><idno type="url">https://api.istex.fr/document/1AA361AFAC1D975EF627F0E0745195D0BC1BD003/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000D92</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">The influence of donor age on the survival of solid and suspension intraparenchymal human embryonic nigral grafts</title><author><name sortKey="Freeman, Thomas B" sort="Freeman, Thomas B" uniqKey="Freeman T" first="Thomas B." last="Freeman">Thomas B. Freeman</name><affiliation><mods:affiliation>Division of Neurosurgery, University of South Florida, Columbia Drive, Suite 730, Tampa, FL 33606, USA</mods:affiliation></affiliation></author><author><name sortKey="Sanberg, Paul R" sort="Sanberg, Paul R" uniqKey="Sanberg P" first="Paul R." last="Sanberg">Paul R. Sanberg</name><affiliation><mods:affiliation>Division of Neurosurgery, University of South Florida, Columbia Drive, Suite 730, Tampa, FL 33606, USA</mods:affiliation></affiliation></author><author><name sortKey="Nauert, G Michael" sort="Nauert, G Michael" uniqKey="Nauert G" first="G. Michael" last="Nauert">G. Michael Nauert</name><affiliation><mods:affiliation>Woman's Center, Tampa, FL, USA</mods:affiliation></affiliation></author><author><name sortKey="Boss, Barbara D" sort="Boss, Barbara D" uniqKey="Boss B" first="Barbara D." last="Boss">Barbara D. Boss</name><affiliation><mods:affiliation>Hana Biologics, Inc., Alameda, CA, USA</mods:affiliation></affiliation></author><author><name sortKey="Spector, Dennis" sort="Spector, Dennis" uniqKey="Spector D" first="Dennis" last="Spector">Dennis Spector</name><affiliation><mods:affiliation>Hana Biologics, Inc., Alameda, CA, USA</mods:affiliation></affiliation></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation><mods:affiliation>Department of Neurology, Mount Sinai Medical Center, New York, NY, USA</mods:affiliation></affiliation></author><author><name sortKey="Kordower, Jeffrey H" sort="Kordower, Jeffrey H" uniqKey="Kordower J" first="Jeffrey H." last="Kordower">Jeffrey H. Kordower</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush Presbyterian Medical Center, Chicago, IL, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Cell Transplantation</title><title level="j" type="abbrev">CTR</title><idno type="ISSN">0963-6897</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1994">1994</date><biblScope unit="volume">4</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="141">141</biblScope><biblScope unit="page" to="154">154</biblScope></imprint><idno type="ISSN">0963-6897</idno></series><idno type="istex">1AA361AFAC1D975EF627F0E0745195D0BC1BD003</idno><idno type="DOI">10.1016/0963-6897(94)00048-O</idno><idno type="PII">0963-6897(94)00048-O</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0963-6897</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In many species, graft survival and graft-derived behavioral recovery are affected by the embryonic donor age. We compared the ability of solid and suspension grafts of human embryonic mesencephalic dopaminergic (DA) neurons at different embryonic stages to survive intraparenchymal transplantation into 6-OHDA lesioned immunosuppressed rats. Suspension grafts survived best when donor age was between postconception (PC) days 34 and 56. Transplants displayed numerous healthy tyrosine hydroxylase immunoreactive (TH-IR) neurons which sent extensive neuritic processes into the host striatum. Suspension grafts survived poorly when donor age was greater than 65 days. Solid implants displayed comparable viability of TH-IR neurons when donor age was between 44 and 65 days. No solid grafts contained TH-IR cells when donor tissue was older than 72 days. The suspension and solid methods of transplantation resulted in comparable survival of robust grafts, but solid grafts resulted in more intergraft variability than suspension grafts, particularly among the more marginal implants. Our results demonstrate that the upper limit for survival of human embryonic DA suspension grafts correlates well with the period of development of the human nigrostriatal pathway. The “window” for donor age of solid human embryonic DA grafts appears to be extended by about 9 days in comparison to suspension grafts. These data suggest that the upper age limit for grafting human mesencephalic DA neurons should be PC day 56 for suspension grafts, and PC day 65 for solid implants. Older donors are likely to produce grafts with fewer surviving DA neurons.</div></front></TEI><istex><corpusName>elsevier</corpusName><author><json:item><name>Thomas B. Freeman</name><affiliations><json:string>Division of Neurosurgery, University of South Florida, Columbia Drive, Suite 730, Tampa, FL 33606, USA</json:string></affiliations></json:item><json:item><name>Paul R. Sanberg</name><affiliations><json:string>Division of Neurosurgery, University of South Florida, Columbia Drive, Suite 730, Tampa, FL 33606, USA</json:string></affiliations></json:item><json:item><name>G.Michael Nauert</name><affiliations><json:string>Woman's Center, Tampa, FL, USA</json:string></affiliations></json:item><json:item><name>Barbara D. Boss</name><affiliations><json:string>Hana Biologics, Inc., Alameda, CA, USA</json:string></affiliations></json:item><json:item><name>Dennis Spector</name><affiliations><json:string>Hana Biologics, Inc., Alameda, CA, USA</json:string></affiliations></json:item><json:item><name>C.Warren Olanow</name><affiliations><json:string>Department of Neurology, Mount Sinai Medical Center, New York, NY, USA</json:string></affiliations></json:item><json:item><name>Jeffrey H. Kordower</name><affiliations><json:string>Department of Neurological Sciences, Rush Presbyterian Medical Center, Chicago, IL, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Transplant</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Fetal</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Dopamine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Nigra</value></json:item></subject><language><json:string>eng</json:string></language><abstract>In many species, graft survival and graft-derived behavioral recovery are affected by the embryonic donor age. We compared the ability of solid and suspension grafts of human embryonic mesencephalic dopaminergic (DA) neurons at different embryonic stages to survive intraparenchymal transplantation into 6-OHDA lesioned immunosuppressed rats. Suspension grafts survived best when donor age was between postconception (PC) days 34 and 56. Transplants displayed numerous healthy tyrosine hydroxylase immunoreactive (TH-IR) neurons which sent extensive neuritic processes into the host striatum. Suspension grafts survived poorly when donor age was greater than 65 days. Solid implants displayed comparable viability of TH-IR neurons when donor age was between 44 and 65 days. No solid grafts contained TH-IR cells when donor tissue was older than 72 days. The suspension and solid methods of transplantation resulted in comparable survival of robust grafts, but solid grafts resulted in more intergraft variability than suspension grafts, particularly among the more marginal implants. Our results demonstrate that the upper limit for survival of human embryonic DA suspension grafts correlates well with the period of development of the human nigrostriatal pathway. The “window” for donor age of solid human embryonic DA grafts appears to be extended by about 9 days in comparison to suspension grafts. These data suggest that the upper age limit for grafting human mesencephalic DA neurons should be PC day 56 for suspension grafts, and PC day 65 for solid implants. Older donors are likely to produce grafts with fewer surviving DA neurons.</abstract><qualityIndicators><score>7.928</score><pdfVersion>1.2</pdfVersion><pdfPageSize>612 x 828 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1641</abstractCharCount><pdfWordCount>7342</pdfWordCount><pdfCharCount>47276</pdfCharCount><pdfPageCount>14</pdfPageCount><abstractWordCount>244</abstractWordCount></qualityIndicators><title>The influence of donor age on the survival of solid and suspension intraparenchymal human embryonic nigral grafts</title><pii><json:string>0963-6897(94)00048-O</json:string></pii><genre><json:string>research-article</json:string></genre><serie><volume>44</volume><pages><first>A324</first></pages><genre></genre><language><json:string>unknown</json:string></language><title>Am. Acad. Neurol. Conf. Abst. Neurology</title></serie><host><volume>4</volume><pii><json:string>S0963-6897(00)X0012-7</json:string></pii><pages><last>154</last><first>141</first></pages><issn><json:string>0963-6897</json:string></issn><issue>1</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><title>Cell Transplantation</title><publicationDate>1995</publicationDate></host><categories><wos><json:string>MEDICINE, RESEARCH & EXPERIMENTAL</json:string><json:string>TRANSPLANTATION</json:string><json:string>CELL & TISSUE ENGINEERING</json:string><json:string>CELL BIOLOGY</json:string></wos></categories><publicationDate>1994</publicationDate><copyrightDate>1995</copyrightDate><doi><json:string>10.1016/0963-6897(94)00048-O</json:string></doi><id>1AA361AFAC1D975EF627F0E0745195D0BC1BD003</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/1AA361AFAC1D975EF627F0E0745195D0BC1BD003/fulltext/pdf</uri></json:item><json:item><original>true</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/1AA361AFAC1D975EF627F0E0745195D0BC1BD003/fulltext/txt</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/1AA361AFAC1D975EF627F0E0745195D0BC1BD003/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/1AA361AFAC1D975EF627F0E0745195D0BC1BD003/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">The influence of donor age on the survival of solid and suspension intraparenchymal human embryonic nigral grafts</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>ELSEVIER</p></availability><date>1995</date></publicationStmt><notesStmt><note type="content">Section title: Original contribution</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">The influence of donor age on the survival of solid and suspension intraparenchymal human embryonic nigral grafts</title><author><persName><forename type="first">Thomas B.</forename><surname>Freeman</surname></persName><affiliation>To whom correspondence should be addressed.</affiliation><affiliation>Division of Neurosurgery, University of South Florida, Columbia Drive, Suite 730, Tampa, FL 33606, USA</affiliation></author><author><persName><forename type="first">Paul R.</forename><surname>Sanberg</surname></persName><affiliation>Division of Neurosurgery, University of South Florida, Columbia Drive, Suite 730, Tampa, FL 33606, USA</affiliation></author><author><persName><forename type="first">G.Michael</forename><surname>Nauert</surname></persName><affiliation>Woman's Center, Tampa, FL, USA</affiliation></author><author><persName><forename type="first">Barbara D.</forename><surname>Boss</surname></persName><affiliation>Hana Biologics, Inc., Alameda, CA, USA</affiliation></author><author><persName><forename type="first">Dennis</forename><surname>Spector</surname></persName><affiliation>Hana Biologics, Inc., Alameda, CA, USA</affiliation></author><author><persName><forename type="first">C.Warren</forename><surname>Olanow</surname></persName><affiliation>Department of Neurology, Mount Sinai Medical Center, New York, NY, USA</affiliation></author><author><persName><forename type="first">Jeffrey H.</forename><surname>Kordower</surname></persName><affiliation>Department of Neurological Sciences, Rush Presbyterian Medical Center, Chicago, IL, USA</affiliation></author></analytic><monogr><title level="j">Cell Transplantation</title><title level="j" type="abbrev">CTR</title><idno type="pISSN">0963-6897</idno><idno type="PII">S0963-6897(00)X0012-7</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1994"></date><biblScope unit="volume">4</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="141">141</biblScope><biblScope unit="page" to="154">154</biblScope></imprint></monogr><idno type="istex">1AA361AFAC1D975EF627F0E0745195D0BC1BD003</idno><idno type="DOI">10.1016/0963-6897(94)00048-O</idno><idno type="PII">0963-6897(94)00048-O</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1995</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>In many species, graft survival and graft-derived behavioral recovery are affected by the embryonic donor age. We compared the ability of solid and suspension grafts of human embryonic mesencephalic dopaminergic (DA) neurons at different embryonic stages to survive intraparenchymal transplantation into 6-OHDA lesioned immunosuppressed rats. Suspension grafts survived best when donor age was between postconception (PC) days 34 and 56. Transplants displayed numerous healthy tyrosine hydroxylase immunoreactive (TH-IR) neurons which sent extensive neuritic processes into the host striatum. Suspension grafts survived poorly when donor age was greater than 65 days. Solid implants displayed comparable viability of TH-IR neurons when donor age was between 44 and 65 days. No solid grafts contained TH-IR cells when donor tissue was older than 72 days. The suspension and solid methods of transplantation resulted in comparable survival of robust grafts, but solid grafts resulted in more intergraft variability than suspension grafts, particularly among the more marginal implants. Our results demonstrate that the upper limit for survival of human embryonic DA suspension grafts correlates well with the period of development of the human nigrostriatal pathway. The “window” for donor age of solid human embryonic DA grafts appears to be extended by about 9 days in comparison to suspension grafts. These data suggest that the upper age limit for grafting human mesencephalic DA neurons should be PC day 56 for suspension grafts, and PC day 65 for solid implants. Older donors are likely to produce grafts with fewer surviving DA neurons.</p></abstract><textClass><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>Transplant</term></item><item><term>Fetal</term></item><item><term>Dopamine</term></item><item><term>Nigra</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1994-09-06">Registration</change><change when="1994">Published</change></revisionDesc></teiHeader></istex:fulltextTEI></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>CTR</jid><aid>9400048O</aid><ce:pii>0963-6897(94)00048-O</ce:pii><ce:doi>10.1016/0963-6897(94)00048-O</ce:doi><ce:copyright type="unknown" year="1995"></ce:copyright></item-info><head><ce:dochead><ce:textfn>Original contribution</ce:textfn></ce:dochead><ce:title>The influence of donor age on the survival of solid and suspension intraparenchymal human embryonic nigral grafts</ce:title><ce:author-group><ce:author><ce:given-name>Thomas B.</ce:given-name><ce:surname>Freeman</ce:surname><ce:cross-ref refid="COR1"><ce:sup>1</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF1"><ce:sup>∗</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF2"><ce:sup>†</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Paul R.</ce:given-name><ce:surname>Sanberg</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>∗</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF2"><ce:sup>†</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF3"><ce:sup>‡</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>G.Michael</ce:given-name><ce:surname>Nauert</ce:surname><ce:cross-ref refid="AFF4"><ce:sup>§</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Barbara D.</ce:given-name><ce:surname>Boss</ce:surname><ce:cross-ref refid="AFF5"><ce:sup>¶</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Dennis</ce:given-name><ce:surname>Spector</ce:surname><ce:cross-ref refid="AFF5"><ce:sup>¶</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>C.Warren</ce:given-name><ce:surname>Olanow</ce:surname><ce:cross-ref refid="AFF6"><ce:sup>∥</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Jeffrey H.</ce:given-name><ce:surname>Kordower</ce:surname><ce:cross-ref refid="AFF7"><ce:sup>#</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="AFF1"><ce:label>a</ce:label><ce:textfn>Division of Neurosurgery, University of South Florida, Columbia Drive, Suite 730, Tampa, FL 33606, USA</ce:textfn></ce:affiliation><ce:affiliation id="AFF2"><ce:label>b</ce:label><ce:textfn>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Columbia Drive, Suite 730, Tampa, FL 33606, USA</ce:textfn></ce:affiliation><ce:affiliation id="AFF3"><ce:label>c</ce:label><ce:textfn>Department of Psychiatry, University of South Florida, Columbia Drive, Suite 730, Tampa, FL 33606, USA</ce:textfn></ce:affiliation><ce:affiliation id="AFF4"><ce:label>d</ce:label><ce:textfn>Woman's Center, Tampa, FL, USA</ce:textfn></ce:affiliation><ce:affiliation id="AFF5"><ce:label>e</ce:label><ce:textfn>Hana Biologics, Inc., Alameda, CA, USA</ce:textfn></ce:affiliation><ce:affiliation id="AFF6"><ce:label>f</ce:label><ce:textfn>Department of Neurology, Mount Sinai Medical Center, New York, NY, USA</ce:textfn></ce:affiliation><ce:affiliation id="AFF7"><ce:label>g</ce:label><ce:textfn>Department of Neurological Sciences, Rush Presbyterian Medical Center, Chicago, IL, USA</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>1</ce:label><ce:text>To whom correspondence should be addressed.</ce:text></ce:correspondence></ce:author-group><ce:date-accepted day="6" month="9" year="1994"></ce:date-accepted><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>In many species, graft survival and graft-derived behavioral recovery are affected by the embryonic donor age. We compared the ability of solid and suspension grafts of human embryonic mesencephalic dopaminergic (DA) neurons at different embryonic stages to survive intraparenchymal transplantation into 6-OHDA lesioned immunosuppressed rats. Suspension grafts survived best when donor age was between postconception (PC) days 34 and 56. Transplants displayed numerous healthy tyrosine hydroxylase immunoreactive (TH-IR) neurons which sent extensive neuritic processes into the host striatum. Suspension grafts survived poorly when donor age was greater than 65 days. Solid implants displayed comparable viability of TH-IR neurons when donor age was between 44 and 65 days. No solid grafts contained TH-IR cells when donor tissue was older than 72 days. The suspension and solid methods of transplantation resulted in comparable survival of robust grafts, but solid grafts resulted in more intergraft variability than suspension grafts, particularly among the more marginal implants. Our results demonstrate that the upper limit for survival of human embryonic DA suspension grafts correlates well with the period of development of the human nigrostriatal pathway. The “window” for donor age of solid human embryonic DA grafts appears to be extended by about 9 days in comparison to suspension grafts. These data suggest that the upper age limit for grafting human mesencephalic DA neurons should be PC day 56 for suspension grafts, and PC day 65 for solid implants. Older donors are likely to produce grafts with fewer surviving DA neurons.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>Parkinson's disease</ce:text></ce:keyword><ce:keyword><ce:text>Transplant</ce:text></ce:keyword><ce:keyword><ce:text>Fetal</ce:text></ce:keyword><ce:keyword><ce:text>Dopamine</ce:text></ce:keyword><ce:keyword><ce:text>Nigra</ce:text></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>The influence of donor age on the survival of solid and suspension intraparenchymal human embryonic nigral grafts</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>The influence of donor age on the survival of solid and suspension intraparenchymal human embryonic nigral grafts</title></titleInfo><name type="personal"><namePart type="given">Thomas B.</namePart><namePart type="family">Freeman</namePart><affiliation>Division of Neurosurgery, University of South Florida, Columbia Drive, Suite 730, Tampa, FL 33606, USA</affiliation><description>To whom correspondence should be addressed.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Paul R.</namePart><namePart type="family">Sanberg</namePart><affiliation>Division of Neurosurgery, University of South Florida, Columbia Drive, Suite 730, Tampa, FL 33606, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G.Michael</namePart><namePart type="family">Nauert</namePart><affiliation>Woman's Center, Tampa, FL, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Barbara D.</namePart><namePart type="family">Boss</namePart><affiliation>Hana Biologics, Inc., Alameda, CA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Dennis</namePart><namePart type="family">Spector</namePart><affiliation>Hana Biologics, Inc., Alameda, CA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.Warren</namePart><namePart type="family">Olanow</namePart><affiliation>Department of Neurology, Mount Sinai Medical Center, New York, NY, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jeffrey H.</namePart><namePart type="family">Kordower</namePart><affiliation>Department of Neurological Sciences, Rush Presbyterian Medical Center, Chicago, IL, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article"></genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1994</dateIssued><dateValid encoding="w3cdtf">1994-09-06</dateValid><copyrightDate encoding="w3cdtf">1995</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">In many species, graft survival and graft-derived behavioral recovery are affected by the embryonic donor age. We compared the ability of solid and suspension grafts of human embryonic mesencephalic dopaminergic (DA) neurons at different embryonic stages to survive intraparenchymal transplantation into 6-OHDA lesioned immunosuppressed rats. Suspension grafts survived best when donor age was between postconception (PC) days 34 and 56. Transplants displayed numerous healthy tyrosine hydroxylase immunoreactive (TH-IR) neurons which sent extensive neuritic processes into the host striatum. Suspension grafts survived poorly when donor age was greater than 65 days. Solid implants displayed comparable viability of TH-IR neurons when donor age was between 44 and 65 days. No solid grafts contained TH-IR cells when donor tissue was older than 72 days. The suspension and solid methods of transplantation resulted in comparable survival of robust grafts, but solid grafts resulted in more intergraft variability than suspension grafts, particularly among the more marginal implants. Our results demonstrate that the upper limit for survival of human embryonic DA suspension grafts correlates well with the period of development of the human nigrostriatal pathway. The “window” for donor age of solid human embryonic DA grafts appears to be extended by about 9 days in comparison to suspension grafts. These data suggest that the upper age limit for grafting human mesencephalic DA neurons should be PC day 56 for suspension grafts, and PC day 65 for solid implants. Older donors are likely to produce grafts with fewer surviving DA neurons.</abstract><note type="content">Section title: Original contribution</note><subject><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>Transplant</topic><topic>Fetal</topic><topic>Dopamine</topic><topic>Nigra</topic></subject><relatedItem type="host"><titleInfo><title>Cell Transplantation</title></titleInfo><titleInfo type="abbreviated"><title>CTR</title></titleInfo><genre type="Journal">journal</genre><originInfo><dateIssued encoding="w3cdtf">199501</dateIssued></originInfo><identifier type="ISSN">0963-6897</identifier><identifier type="PII">S0963-6897(00)X0012-7</identifier><part><date>199501</date><detail type="issue"><title>Neural Transplantation into the CNS</title></detail><detail type="volume"><number>4</number><caption>vol.</caption></detail><detail type="issue"><number>1</number><caption>no.</caption></detail><extent unit="issue pages"><start>1</start><end>154</end></extent><extent unit="pages"><start>141</start><end>154</end></extent></part></relatedItem><identifier type="istex">1AA361AFAC1D975EF627F0E0745195D0BC1BD003</identifier><identifier type="DOI">10.1016/0963-6897(94)00048-O</identifier><identifier type="PII">0963-6897(94)00048-O</identifier><recordInfo><recordContentSource>ELSEVIER</recordContentSource></recordInfo></mods></metadata><enrichments><istex:catWosTEI uri="https://api.istex.fr/document/1AA361AFAC1D975EF627F0E0745195D0BC1BD003/enrichments/catWos"><teiHeader><profileDesc><textClass><classCode scheme="WOS">MEDICINE, RESEARCH & EXPERIMENTAL</classCode><classCode scheme="WOS">TRANSPLANTATION</classCode><classCode scheme="WOS">CELL & TISSUE ENGINEERING</classCode><classCode scheme="WOS">CELL BIOLOGY</classCode></textClass></profileDesc></teiHeader></istex:catWosTEI></enrichments></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D92 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000D92 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:1AA361AFAC1D975EF627F0E0745195D0BC1BD003
|texte= The influence of donor age on the survival of solid and suspension intraparenchymal human embryonic nigral grafts
}}
| This area was generated with Dilib version V0.6.23. |  |